APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumour Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Tumour Vaccine Industry Growth and Trends Forecast to 2032

31 December 2025124 pages

Choose your research edition.

Industry ResearchTumour Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumour Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumour Vaccine Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumour Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

According to APO Research, the global Tumour Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Tumour Vaccine market include Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals and Medigene AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Tumour Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Tumour Vaccine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tumour Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tumour Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Tumour Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Tumour Vaccine Market by Company

Advaxis

Agenus Inc

Avidea Technologies

BioNTech

BrightPath Biotherapeutics

Genocea Biosciences Inc

Gritstone Bio

ISA Pharmaceuticals

Medigene AG

Moderna

Nouscom

Novogene

OSE Immunotherapeutics

Roche Holding AG

Vaccibody AS

Vaximm AG

ZIOPHARM Oncology

Pfizer

Eli Lilly and Company

Merck & Co Inc

Tumour Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Tumour Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Tumour Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumour Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumour Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumour Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Tumour Vaccine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Tumour Vaccine Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Tumour Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Tumour Vaccine Market Share by Region (2021-2026) Table 4. Global Tumour Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Tumour Vaccine Market Share by Region (2027-2032) Table 6. Global Tumour Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Tumour Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Tumour Vaccine Market Size Share by Type (2021-2026) Table 9. Global Tumour Vaccine Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Tumour Vaccine Market Size Share Forecasted by Type (2027-2032) Table 11. North America Tumour Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Tumour Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Tumour Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Tumour Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Tumour Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Tumour Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Tumour Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Tumour Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Tumour Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Tumour Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Tumour Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Tumour Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Tumour Vaccine Market Size Share by Application (2021-2026) Table 24. Global Tumour Vaccine Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Tumour Vaccine Market Size Share Forecasted by Application (2027-2032) Table 26. North America Tumour Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Tumour Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Tumour Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Tumour Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Tumour Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Tumour Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Tumour Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Tumour Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Tumour Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Tumour Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Tumour Vaccine Industry Trends Table 37. Tumour Vaccine Industry Drivers Table 38. Tumour Vaccine Industry Opportunities and Challenges Table 39. Tumour Vaccine Industry Restraints Table 40. Global Tumour Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Tumour Vaccine Revenue Market Share by Company (2021-2026) Table 42. Global Tumour Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Tumour Vaccine Key Company Headquarters & Area Served Table 44. Global Tumour Vaccine Company, Product Type & Application Table 45. Global Tumour Vaccine Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Tumour Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Advaxis Company Information Table 49. Advaxis Business Overview Table 50. Advaxis Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Advaxis Tumour Vaccine Product Portfolio Table 52. Advaxis Recent Development Table 53. Agenus Inc Company Information Table 54. Agenus Inc Business Overview Table 55. Agenus Inc Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Agenus Inc Tumour Vaccine Product Portfolio Table 57. Agenus Inc Recent Development Table 58. Avidea Technologies Company Information Table 59. Avidea Technologies Business Overview Table 60. Avidea Technologies Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Avidea Technologies Tumour Vaccine Product Portfolio Table 62. Avidea Technologies Recent Development Table 63. BioNTech Company Information Table 64. BioNTech Business Overview Table 65. BioNTech Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. BioNTech Tumour Vaccine Product Portfolio Table 67. BioNTech Recent Development Table 68. BrightPath Biotherapeutics Company Information Table 69. BrightPath Biotherapeutics Business Overview Table 70. BrightPath Biotherapeutics Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. BrightPath Biotherapeutics Tumour Vaccine Product Portfolio Table 72. BrightPath Biotherapeutics Recent Development Table 73. Genocea Biosciences Inc Company Information Table 74. Genocea Biosciences Inc Business Overview Table 75. Genocea Biosciences Inc Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Genocea Biosciences Inc Tumour Vaccine Product Portfolio Table 77. Genocea Biosciences Inc Recent Development Table 78. Gritstone Bio Company Information Table 79. Gritstone Bio Business Overview Table 80. Gritstone Bio Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Gritstone Bio Tumour Vaccine Product Portfolio Table 82. Gritstone Bio Recent Development Table 83. ISA Pharmaceuticals Company Information Table 84. ISA Pharmaceuticals Business Overview Table 85. ISA Pharmaceuticals Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. ISA Pharmaceuticals Tumour Vaccine Product Portfolio Table 87. ISA Pharmaceuticals Recent Development Table 88. Medigene AG Company Information Table 89. Medigene AG Business Overview Table 90. Medigene AG Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Medigene AG Tumour Vaccine Product Portfolio Table 92. Medigene AG Recent Development Table 93. Moderna Company Information Table 94. Moderna Business Overview Table 95. Moderna Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Moderna Tumour Vaccine Product Portfolio Table 97. Moderna Recent Development Table 98. Nouscom Company Information Table 99. Nouscom Business Overview Table 100. Nouscom Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Nouscom Tumour Vaccine Product Portfolio Table 102. Nouscom Recent Development Table 103. Novogene Company Information Table 104. Novogene Business Overview Table 105. Novogene Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Novogene Tumour Vaccine Product Portfolio Table 107. Novogene Recent Development Table 108. OSE Immunotherapeutics Company Information Table 109. OSE Immunotherapeutics Business Overview Table 110. OSE Immunotherapeutics Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. OSE Immunotherapeutics Tumour Vaccine Product Portfolio Table 112. OSE Immunotherapeutics Recent Development Table 113. Roche Holding AG Company Information Table 114. Roche Holding AG Business Overview Table 115. Roche Holding AG Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Roche Holding AG Tumour Vaccine Product Portfolio Table 117. Roche Holding AG Recent Development Table 118. Vaccibody AS Company Information Table 119. Vaccibody AS Business Overview Table 120. Vaccibody AS Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Vaccibody AS Tumour Vaccine Product Portfolio Table 122. Vaccibody AS Recent Development Table 123. Vaximm AG Company Information Table 124. Vaximm AG Business Overview Table 125. Vaximm AG Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Vaximm AG Tumour Vaccine Product Portfolio Table 127. Vaximm AG Recent Development Table 128. ZIOPHARM Oncology Company Information Table 129. ZIOPHARM Oncology Business Overview Table 130. ZIOPHARM Oncology Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. ZIOPHARM Oncology Tumour Vaccine Product Portfolio Table 132. ZIOPHARM Oncology Recent Development Table 133. Pfizer Company Information Table 134. Pfizer Business Overview Table 135. Pfizer Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Pfizer Tumour Vaccine Product Portfolio Table 137. Pfizer Recent Development Table 138. Eli Lilly and Company Company Information Table 139. Eli Lilly and Company Business Overview Table 140. Eli Lilly and Company Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Eli Lilly and Company Tumour Vaccine Product Portfolio Table 142. Eli Lilly and Company Recent Development Table 143. Merck & Co Inc Company Information Table 144. Merck & Co Inc Business Overview Table 145. Merck & Co Inc Tumour Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Merck & Co Inc Tumour Vaccine Product Portfolio Table 147. Merck & Co Inc Recent Development Table 148. North America Tumour Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Tumour Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Tumour Vaccine Market Share by Country (2021-2026) Table 151. North America Tumour Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Tumour Vaccine Market Share Forecast by Country (2027-2032) Table 153. Europe Tumour Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Tumour Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Tumour Vaccine Market Share by Country (2021-2026) Table 156. Europe Tumour Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Tumour Vaccine Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Tumour Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Tumour Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Tumour Vaccine Market Share by Country (2021-2026) Table 161. Asia-Pacific Tumour Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Tumour Vaccine Market Share Forecast by Country (2027-2032) Table 163. Latin America Tumour Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Tumour Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Tumour Vaccine Market Share by Country (2021-2026) Table 166. Latin America Tumour Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Tumour Vaccine Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Tumour Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Tumour Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Tumour Vaccine Market Share by Country (2021-2026) Table 171. Middle East & Africa Tumour Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Tumour Vaccine Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Tumour Vaccine Product Image Figure 3. Global Tumour Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 5. Global Tumour Vaccine Market Share by Region: 2025 VS 2032 Figure 6. Global Tumour Vaccine Market Share by Region (2021-2032) Figure 7. North America Tumour Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Tumour Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Tumour Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Tumour Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Tumour Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Personalized Vaccine Image Figure 13. Global Personalized Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Off-the shelf Vaccine Image Figure 15. Global Off-the shelf Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Tumour Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Tumour Vaccine Market Share by Type 2025 VS 2032 Figure 18. North America Tumour Vaccine Market Size Share by Type (2021-2032) Figure 19. Europe Tumour Vaccine Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Tumour Vaccine Market Size Share by Type (2021-2032) Figure 21. Latin America Tumour Vaccine Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Tumour Vaccine Market Size Share by Type (2021-2032) Figure 23. Gastrointestinal Cancer Image Figure 24. Global Gastrointestinal Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Lung Cancer Image Figure 26. Global Lung Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Melanoma Cancer Image Figure 28. Global Melanoma Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Brain Cancer Image Figure 30. Global Brain Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Tumour Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Tumour Vaccine Market Share by Application 2025 VS 2032 Figure 35. North America Tumour Vaccine Market Size Share by Application (2021-2032) Figure 36. Europe Tumour Vaccine Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Tumour Vaccine Market Size Share by Application (2021-2032) Figure 38. Latin America Tumour Vaccine Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Tumour Vaccine Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Tumour Vaccine Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Tumour Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Tumour Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Tumour Vaccine Market Share by Country (2021-2032) Figure 45. Europe Tumour Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Tumour Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Tumour Vaccine Market Share by Country (2021-2032) Figure 48. Asia-Pacific Tumour Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Tumour Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Tumour Vaccine Market Share by Country (2021-2032) Figure 51. Latin America Tumour Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Tumour Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Tumour Vaccine Market Share by Country (2021-2032) Figure 54. Middle East & Africa Tumour Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Tumour Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Tumour Vaccine Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Advaxis
  • Agenus Inc
  • Avidea Technologies
  • BioNTech
  • BrightPath Biotherapeutics
  • Genocea Biosciences Inc
  • Gritstone Bio
  • ISA Pharmaceuticals
  • Medigene AG
  • Moderna
  • Nouscom
  • Novogene
  • OSE Immunotherapeutics
  • Roche Holding AG
  • Vaccibody AS
  • Vaximm AG
  • ZIOPHARM Oncology
  • Pfizer
  • Eli Lilly and Company
  • Merck & Co Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Tumour Vaccine Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Tumour Vaccine Market Size by Region (2021-2032)
  5. 1.4.1 Global Tumour Vaccine Market Size by Region (2021-2026)
  6. 1.4.2 Global Tumour Vaccine Market Size by Region (2027-2032)
  7. 1.5 Key Regions Tumour Vaccine Market Size (2021-2032)
  8. 1.5.1 North America Tumour Vaccine Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Tumour Vaccine Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Tumour Vaccine Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Tumour Vaccine Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Tumour Vaccine Market Size Growth Rate (2021-2032)
2 Tumour Vaccine Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Personalized Vaccine
  3. 2.1.2 Off-the shelf Vaccine
  4. 2.2 Global Tumour Vaccine Market Size by Type
  5. 2.2.1 Global Tumour Vaccine Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Tumour Vaccine Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Tumour Vaccine Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Tumour Vaccine Market Size by Regions
  9. 2.3.1 North America Tumour Vaccine Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Tumour Vaccine Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Tumour Vaccine Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Tumour Vaccine Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Tumour Vaccine Market Size Breakdown by Type (2021-2026)
3 Tumour Vaccine Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Gastrointestinal Cancer
  3. 3.1.2 Lung Cancer
  4. 3.1.3 Melanoma Cancer
  5. 3.1.4 Brain Cancer
  6. 3.1.5 Others
  7. 3.2 Global Tumour Vaccine Market Size by Application
  8. 3.2.1 Global Tumour Vaccine Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Tumour Vaccine Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Tumour Vaccine Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Tumour Vaccine Market Size by Regions
  12. 3.3.1 North America Tumour Vaccine Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Tumour Vaccine Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Tumour Vaccine Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Tumour Vaccine Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Tumour Vaccine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Tumour Vaccine Industry Trends
  2. 4.2 Tumour Vaccine Industry Drivers
  3. 4.3 Tumour Vaccine Industry Opportunities and Challenges
  4. 4.4 Tumour Vaccine Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Tumour Vaccine Revenue (2021-2026)
  2. 5.2 Global Tumour Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Tumour Vaccine Key Company Headquarters & Area Served
  4. 5.4 Global Tumour Vaccine Company, Product Type & Application
  5. 5.5 Global Tumour Vaccine Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Tumour Vaccine Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Tumour Vaccine Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Tumour Vaccine Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Advaxis
  2. 6.1.1 Advaxis Company Information
  3. 6.1.2 Advaxis Business Overview
  4. 6.1.3 Advaxis Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Advaxis Tumour Vaccine Product Portfolio
  6. 6.1.5 Advaxis Recent Developments
  7. 6.2 Agenus Inc
  8. 6.2.1 Agenus Inc Company Information
  9. 6.2.2 Agenus Inc Business Overview
  10. 6.2.3 Agenus Inc Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Agenus Inc Tumour Vaccine Product Portfolio
  12. 6.2.5 Agenus Inc Recent Developments
  13. 6.3 Avidea Technologies
  14. 6.3.1 Avidea Technologies Company Information
  15. 6.3.2 Avidea Technologies Business Overview
  16. 6.3.3 Avidea Technologies Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Avidea Technologies Tumour Vaccine Product Portfolio
  18. 6.3.5 Avidea Technologies Recent Developments
  19. 6.4 BioNTech
  20. 6.4.1 BioNTech Company Information
  21. 6.4.2 BioNTech Business Overview
  22. 6.4.3 BioNTech Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 BioNTech Tumour Vaccine Product Portfolio
  24. 6.4.5 BioNTech Recent Developments
  25. 6.5 BrightPath Biotherapeutics
  26. 6.5.1 BrightPath Biotherapeutics Company Information
  27. 6.5.2 BrightPath Biotherapeutics Business Overview
  28. 6.5.3 BrightPath Biotherapeutics Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 BrightPath Biotherapeutics Tumour Vaccine Product Portfolio
  30. 6.5.5 BrightPath Biotherapeutics Recent Developments
  31. 6.6 Genocea Biosciences Inc
  32. 6.6.1 Genocea Biosciences Inc Company Information
  33. 6.6.2 Genocea Biosciences Inc Business Overview
  34. 6.6.3 Genocea Biosciences Inc Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Genocea Biosciences Inc Tumour Vaccine Product Portfolio
  36. 6.6.5 Genocea Biosciences Inc Recent Developments
  37. 6.7 Gritstone Bio
  38. 6.7.1 Gritstone Bio Company Information
  39. 6.7.2 Gritstone Bio Business Overview
  40. 6.7.3 Gritstone Bio Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Gritstone Bio Tumour Vaccine Product Portfolio
  42. 6.7.5 Gritstone Bio Recent Developments
  43. 6.8 ISA Pharmaceuticals
  44. 6.8.1 ISA Pharmaceuticals Company Information
  45. 6.8.2 ISA Pharmaceuticals Business Overview
  46. 6.8.3 ISA Pharmaceuticals Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 ISA Pharmaceuticals Tumour Vaccine Product Portfolio
  48. 6.8.5 ISA Pharmaceuticals Recent Developments
  49. 6.9 Medigene AG
  50. 6.9.1 Medigene AG Company Information
  51. 6.9.2 Medigene AG Business Overview
  52. 6.9.3 Medigene AG Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Medigene AG Tumour Vaccine Product Portfolio
  54. 6.9.5 Medigene AG Recent Developments
  55. 6.10 Moderna
  56. 6.10.1 Moderna Company Information
  57. 6.10.2 Moderna Business Overview
  58. 6.10.3 Moderna Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Moderna Tumour Vaccine Product Portfolio
  60. 6.10.5 Moderna Recent Developments
  61. 6.11 Nouscom
  62. 6.11.1 Nouscom Company Information
  63. 6.11.2 Nouscom Business Overview
  64. 6.11.3 Nouscom Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Nouscom Tumour Vaccine Product Portfolio
  66. 6.11.5 Nouscom Recent Developments
  67. 6.12 Novogene
  68. 6.12.1 Novogene Company Information
  69. 6.12.2 Novogene Business Overview
  70. 6.12.3 Novogene Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Novogene Tumour Vaccine Product Portfolio
  72. 6.12.5 Novogene Recent Developments
  73. 6.13 OSE Immunotherapeutics
  74. 6.13.1 OSE Immunotherapeutics Company Information
  75. 6.13.2 OSE Immunotherapeutics Business Overview
  76. 6.13.3 OSE Immunotherapeutics Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 OSE Immunotherapeutics Tumour Vaccine Product Portfolio
  78. 6.13.5 OSE Immunotherapeutics Recent Developments
  79. 6.14 Roche Holding AG
  80. 6.14.1 Roche Holding AG Company Information
  81. 6.14.2 Roche Holding AG Business Overview
  82. 6.14.3 Roche Holding AG Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Roche Holding AG Tumour Vaccine Product Portfolio
  84. 6.14.5 Roche Holding AG Recent Developments
  85. 6.15 Vaccibody AS
  86. 6.15.1 Vaccibody AS Company Information
  87. 6.15.2 Vaccibody AS Business Overview
  88. 6.15.3 Vaccibody AS Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Vaccibody AS Tumour Vaccine Product Portfolio
  90. 6.15.5 Vaccibody AS Recent Developments
  91. 6.16 Vaximm AG
  92. 6.16.1 Vaximm AG Company Information
  93. 6.16.2 Vaximm AG Business Overview
  94. 6.16.3 Vaximm AG Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Vaximm AG Tumour Vaccine Product Portfolio
  96. 6.16.5 Vaximm AG Recent Developments
  97. 6.17 ZIOPHARM Oncology
  98. 6.17.1 ZIOPHARM Oncology Company Information
  99. 6.17.2 ZIOPHARM Oncology Business Overview
  100. 6.17.3 ZIOPHARM Oncology Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 ZIOPHARM Oncology Tumour Vaccine Product Portfolio
  102. 6.17.5 ZIOPHARM Oncology Recent Developments
  103. 6.18 Pfizer
  104. 6.18.1 Pfizer Company Information
  105. 6.18.2 Pfizer Business Overview
  106. 6.18.3 Pfizer Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Pfizer Tumour Vaccine Product Portfolio
  108. 6.18.5 Pfizer Recent Developments
  109. 6.19 Eli Lilly and Company
  110. 6.19.1 Eli Lilly and Company Company Information
  111. 6.19.2 Eli Lilly and Company Business Overview
  112. 6.19.3 Eli Lilly and Company Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Eli Lilly and Company Tumour Vaccine Product Portfolio
  114. 6.19.5 Eli Lilly and Company Recent Developments
  115. 6.20 Merck & Co Inc
  116. 6.20.1 Merck & Co Inc Company Information
  117. 6.20.2 Merck & Co Inc Business Overview
  118. 6.20.3 Merck & Co Inc Tumour Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Merck & Co Inc Tumour Vaccine Product Portfolio
  120. 6.20.5 Merck & Co Inc Recent Developments
7 North America
  1. 7.1 North America Tumour Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Tumour Vaccine Market Size by Country (2021-2026)
  3. 7.3 North America Tumour Vaccine Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Tumour Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Tumour Vaccine Market Size by Country (2021-2026)
  3. 8.3 Europe Tumour Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Tumour Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Tumour Vaccine Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Tumour Vaccine Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Tumour Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Tumour Vaccine Market Size by Country (2021-2026)
  3. 10.3 South America Tumour Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Tumour Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Tumour Vaccine Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Tumour Vaccine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst